Research

Mixed

Semaglutide 2.4 mg treatment leads to preferential loss of fat mass over lean body mass, which supports improvements in physical function and walking capacity.

Semaglutide 2.4 mg helps you lose fat mass more than lean body mass, which supports your physical function and walking capacity. This is achieved through once-weekly injections combined with lifestyle changes.

GoodSupportsHIGH confidence
Body composition findings showed that reductions in total fat mass were greater with semaglutide versus placebo... weight loss with once-weekly subcutaneous semaglutide 2.4 mg treatment was primarily due to fat loss, rather than lean body mass (muscle)
Patrick M. O’Neil et al. · Postgraduate Medicine · 2022

Why this rating

Based on DEXA measurements in a subgroup of STEP 1, consistent with previous studies.

Source

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

Patrick M. O’Neil et al. · Postgraduate Medicine · 2022

DOI 10.1080/00325481.2022.2150006

narrative_reviewCited 18×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →